OSR Holdings signs $815M VXM01 license with BCM Europe; largest shareholder pledges entire stake as collateral

OSR Holdings, Inc.

Up to $815M in milestone payments from BCM Europe for VXM01 oral immunotherapy platform (Phase 3-ready VEGFR-2 target).
BCM Europe pledges its entire 9,974,728 shares (~29.7% of OSRH) as collateral for milestone obligations; pledge effective Feb 2028.
OSRH to acquire full VXM01 IP from Vaximm AG for $30M via separate asset purchase agreement.
OSRH receives $15M equity put option at $10/share, exercisable after six months post-effective date.
All downstream royalties after BCME recovers investment and preferred return flow to OSRH.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

OSR Holdings, Inc. entered into License Agreement with BCM Europe AG valued at up to $815,000,000 (effective 2026-04-29).

Action: entry
Agreement: license
Counterparty: BCM Europe AG
Value: up to $815,000,000
Effective: 2026-04-29

Exact text from the filing

Global Exclusive License Agreement On April 29, 2026, OSR Holdings, Inc. (the “Company”), together with its wholly-owned subsidiary Vaximm AG (“Vaximm”), entered into a Global Exclusive License Agreement (the “License

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

OSR Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-049967

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.